(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
NASA releases stunning new images captured by the Artemis II moon mission, including 'Earthset' and a solar eclipse from space - 2Flu cases skyrocket in US. See cases, where people got sick.
- 3Instructions to Back Your Sunlight powered chargers: Tracking down Possible Choices
- 4Europe picks companies to help build Argonaut moon lander
- 56 Famous kind of practice on the planet
- Fundamental Home Exercise center Hardware: Amplify Your Exercises
- Figure out How to Score Huge with Open Record Rewards
- My prescription costs what?! Pharmacists offer tips that could reduce your out-of-pocket drug costs
- Fuel Price Spike Drives Surge in Used EV Sales in Europe
- When a sperm whale gives birth, the mother gets help from her friends
- How a Middle East War Becomes a Retail Price Hike
- Picking the Right Pot for Your Plants: An Aide for Plant Devotees
- IDF, police arrest eleven for criminal, terror-related activity over weekend
- Social Skylines d: A Survey of \Inside and out Social Experiences\ Language Learning Book
